文献速递腹部CT

CT估算细胞外间隙分数预测胰腺导管腺癌化疗反应与生存

Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · AJR Am J Roentgenol · 2020-07-01

本研究探讨治疗前CT估算的原发胰腺导管腺癌细胞外间隙分数(fECS)与化疗反应及患者结局的关联。高fECS(>0.41)组疾病控制比例及无进展生存期均优于低fECS组,fECS是无进展生存期的独立预测因子。

要点

  • 治疗前CT估算的原发肿瘤fECS中位值为0.41(范围0.02-0.69)。
  • fECS>0.41组疾病控制比例高于≤0.41组:全队列27/30 vs 19/30(p=0.030)。
  • 高fECS组无进展生存期长于低fECS组:191天 vs 115天(p<0.0001)。

核心结论

  • 治疗前CT估算的高原发肿瘤fECS值与晚期胰腺导管腺癌化疗反应及无进展生存期相关。

研究设计与样本

  • 本研究为数据库检索研究,纳入接受全身治疗的局部晚期或转移性胰腺导管腺癌患者,其治疗前CT包含平扫和平衡期图像。
  • 在肿瘤和主动脉上放置ROI,fECS计算公式为:(平衡期肿瘤衰减-平扫肿瘤衰减)/(平衡期主动脉衰减-平扫主动脉衰减)×(1-血细胞比容)。
  • 疗效依据实体瘤疗效评价标准1.1版在后续CT检查中评估,并记录糖类抗原19-9水平、化疗方案和生存等临床变量,采用多变量分析确定治疗反应和患者生存的预测因子。

诊断标准与关键数值

  • 原发肿瘤fECS中位值为0.41(范围0.02-0.69),以>0.41为高值、≤0.41为低值进行二分类。
  • 高fECS组疾病控制比例:全队列27/30 vs 低fECS组19/30(p=0.030);局部晚期队列23/24 vs 10/15(p=0.024)。
  • 高fECS组平均无进展生存期191天 vs 低fECS组115天(p<0.0001)。
  • 多变量分析显示原发肿瘤fECS是无进展生存期的独立预测因子(p=0.003)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to investigate the association between primary pancreatic ductal adenocarcinoma fractional extracellular space (fECS) estimated from pretreatment CT and tumor response to chemotherapy and patient outcome. MATERIALS AND METHODS. A database search identified the records of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma treated with systemic therapies who had undergone pretreatment CT that included both unenhanced and equilibrium phase images. An ROI was placed on the primary tumor and aorta, and the tumor fECS was calculated as follows: (tumor attenuation in the equilibrium phase - tumor attenuation in the unenhanced phase) / (aortic attenuation in the equilibrium phase - aortic attenuation in the unenhanced phase) × (1 - hematocrit). Response to therapy was assessed in subsequent CT examinations according to the Response Evaluation Criteria in Solid Tumors version 1.1. Relevant clinical variables, including carbohydrate antigen 19-9 level, chemotherapy regimen, and survival were recorded. Multivariate analyses were performed to determine the predictors of treatment response and patient survival. RESULTS. The median primary tumor fECS was 0.41 (range, 0.02-0.69). When dichotomized to high (> 0.41) versus low fECS (≤ 0.41) values, a larger proportion of patients with high tumor fECS values achieved disease control after chemotherapy than did those with low tumor fECS values: full cohort, 27 of 30 versus 19 of 30 (p = 0.030); cohort with locally advanced disease, 23 of 24 versus 10 of 15 (p = 0.024). The mean progression-free survival among patients with high primary tumor fECS values was significantly longer than that among those with low fECS values (191 versus 115 days, p = < 0.0001). Primary tumor fECS was an independent predictor of progression-free survival (p = 0.003) in multivariate analysis. CONCLUSION. High primary tumor fECS value estimated from staging CT was associated with chemotherapy response and progression-free survival of patients with advanced pancreatic ductal adenocarcinoma.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Wang ZJ, Zhang TT, An C, et al. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020. PMID: 32755156. doi:10.2214/AJR.19.22462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。